---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-097546"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:14:22.028446+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# enGene enters $100M at-the-market equity facility with Leerink Partners

## Summary
- New Sales Agreement with Leerink Partners for up to $100M in common shares via at-the-market offerings.
- Prior Open Market Sale Agreement with Jefferies LLC terminated on March 6, 2026; no shares sold and no penalties.
- Leerink will receive a commission of up to 3.0% of gross proceeds; Company may reimburse certain expenses.
- Shares will be sold under Rule 415(a)(4); Company not obligated to sell any shares.
- No shares offered or sold in Canada under the new agreement.

## SEC filing metadata
- accession: 0001193125-26-097546
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/0001193125-26-097546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/engn-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-097546
- JSON: https://secwatch.observer/filing/0001193125-26-097546.json
- Plain text: https://secwatch.observer/filing/0001193125-26-097546.txt

## Key facts
- Material Agreements
  enGene Therapeutics Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $100,000,000 (effective 2026-03-09).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Leerink Partners LLC
  - Value: up to $100,000,000
  - Effective: 2026-03-09
  source text: On March 9, 2026, enGene Holdings Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), pursuant to which the Company may sell its common shares, without par value (the “Common Shares”), from time to time through Leerink Partners.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/0001193125-26-097546-index.htm
- Material Agreements
  enGene Therapeutics Inc. terminated Open Market Sale Agreement with Jefferies LLC valued at terminated Prior Sales Agreement; no shares sold (effective 2026-02-27).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: terminated Prior Sales Agreement; no shares sold
  - Effective: 2026-02-27
  source text: On February 27, 2026, the Company delivered written notice to Jefferies LLC that effective as of March 6, 2026, the Company terminated the Open Market Sale Agreement SM , dated as of December 20, 2024 (the “Prior Sales Agreement”), that the Company had previously entered into with Jefferies LLC, as sales agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/0001193125-26-097546-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.